메뉴 건너뛰기




Volumn 19, Issue 2, 1998, Pages 49-59

A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin®

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

EID: 0031913501     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (32)

References (16)
  • 1
    • 0029026110 scopus 로고
    • Goyan JE. Bioequivalence and narrow therapeutic index drugs.
    • Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy. 1995;15: 433-440.
    • (1995) Pharmacotherapy. , vol.15 , pp. 433-440
    • Benet, L.Z.1
  • 2
    • 0028786997 scopus 로고
    • Dalen JE, DeyKim D
    • Hirsch J, Dalen JE, DeyKim D, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest. 1995; 108 (Suppl 6): 231-246.
    • (1995) Chest. , vol.108 , Issue.6 SUPPL. , pp. 231-246
    • Hirsch, J.1
  • 3
    • 33847434992 scopus 로고
    • Rockville, M.D.-23 Convention Inc
    • United States Pharmacopeia. Uniformity of dosing units. Rockville, M.D.-23 Convention Inc; 1995.
    • (1995) Uniformity of Dosing Units.
  • 4
    • 0025334006 scopus 로고
    • Power of the two one-sided tests procedure in bioequivalence
    • Phillips, K.F. Power of the two one-sided tests procedure in bioequivalence.J. Phannacokin, Biopharm. 1990; 18: 137-144.
    • (1990) J. Phannacokin, Biopharm. , vol.18 , pp. 137-144
    • Phillips, K.F.1
  • 7
    • 0023914694 scopus 로고    scopus 로고
    • Medical and economic consequences of blinded oral anticoagulation brand change at a municipal hospital
    • Richton-Hewitt S, Foster E, Apstein CS. Medical and economic consequences of blinded oral anticoagulation brand change at a municipal hospital. A rch Intern Med. 1988;148:806-808.
    • A Rch Intern Med. , vol.1988 , pp. 806-808
    • Richton-Hewitt, S.1    Foster, E.2    Apstein, C.S.3
  • 8
    • 33847444776 scopus 로고    scopus 로고
    • Davis RO, Gagno MA. Drug bioavailability.
    • Ruedy J, Davis RO, Gagno MA. Drug bioavailability. CanMedAssocJ. 1976;! 15:105.
    • CanMedAssocJ. 1976;! , vol.15 , pp. 105
    • Ruedy, J.1
  • 9
    • 0015053518 scopus 로고    scopus 로고
    • In vivo and vitro availability of commercial Warfarin tablets
    • Wagner JG, Welling PG, Kwang PL, et al. In vivo and vitro availability of commercial Warfarin tablets. J Phann Sei. 1971:60:666-677.
    • J Phann Sei. 1971 , pp. 666-677
    • Wagner, J.G.1    Welling, P.G.2    Kwang, P.L.3
  • 10
    • 0024210974 scopus 로고
    • Warfarin bioavailability: A comparison of 6 products
    • Muller FO, Steyn JM, Hundt HK, et al. Warfarin bioavailability: A comparison of 6 products. SAfrMedJ. 1988;76: 11:566-567.
    • (1988) SAfrMedJ. , vol.76 , pp. 566-567
    • Muller, F.O.1    Steyn, J.M.2    Hundt, H.K.3
  • 11
    • 0018427837 scopus 로고
    • Comparison of a new microcrystalline dicoumarol preparation with Warfarin under routine treatment conditions
    • Lockner D, Paul C. Comparison of a new microcrystalline dicoumarol preparation with Warfarin under routine treatment conditions. BrJ Clin Pharmacol. 1979; 8:1:59-64.
    • (1979) BrJ Clin Pharmacol. , vol.8 , pp. 59-64
    • Lockner, D.1    Paul, C.2
  • 12
    • 0030742078 scopus 로고    scopus 로고
    • Generic warfarin: Implications for patient care
    • Wittkowsky AK. Generic warfarin: Implications for patient care. Pharmocolherapy. 1997;17:640-643.
    • (1997) Pharmocolherapy. , vol.17 , pp. 640-643
    • Wittkowsky, A.K.1
  • 15
    • 0028887043 scopus 로고
    • Variations in prothrombin time and international normalized ratio over 24 hours in Warfarin treated patients
    • Bleske BE, Welage LS, Warren EW, et al. Variations in prothrombin time and international normalized ratio over 24 hours in Warfarin treated patients. Pharmacotherapy. 1995; 15:709-7012.
    • (1995) Pharmacotherapy. , vol.15 , pp. 709-7012
    • Bleske, B.E.1    Welage, L.S.2    Warren, E.W.3
  • 16
    • 33847428413 scopus 로고    scopus 로고
    • ANDA submission package to the PDA. Barr Laboratories, Inc. Data on file.
    • ANDA submission package to the PDA. Barr Laboratories, Inc. Data on file.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.